ERC Form 2B: Requirement Checklist for Initial Submission



REQUIREMENT CHECKLIST FOR INITIAL SUBMISSION

STUDY PROTOCOL INFORMATION

RIHS ERC Code:	
(to be assigned by the ERC)	
Study Protocol Title:	
Principal Investigator:	
Study Protocol Submission Date:	

Basic Documents (must submit) (to be checked and verified by the ERC Secretariat):

- □ [RIHS ERC FORM 2(B)] Requirement Checklist for Initial Submission
- □ [RIHS ERC FORM 2(C)] Printed Registration and Application
- **[RIHS ERC FORM 2 (J)]** Review of Resubmitted Protocol
- □ [RIHS ERC FORM 2(D)] Study Protocol Assessment
- □ Study Protocol
- □ Study Protocol Synopsis
- [**RIHS ERC FORM 2(E)**] Informed Consent Assessment (for studies with human participants)
- Data Collection Forms (including CRFs)
- □ CV of PI and study team members
- □ Informed consent form in English (for studies with human participants)
- □ Informed consent form in local language (for studies with human participants)
- □ Assent form in English (for studies involving minors and relevant populations deemed incompetent to sign an informed consent form)
- □ Assent form in local language (for studies involving minors and relevant populations deemed incompetent to sign an informed consent form)
- Good Clinical Practice (GCP) Training Certificate of PI, Co-I and the rest of the study team (for clinical trials)
- Electronic copy of study protocol, RIHS ERC FORM 2(B), RIHS ERC FORM 2(C), RIHS ERC FORM 2(C), and RIHS ERC FORM 2(E) for initial submission
- □ Electronic copy of study protocol and RIHS ERC FORM 2(J), RIHS ERC FORM 2(D), and RIHS ERC FORM 2(E) for resubmission
 - 1ERC Form 2B: Requirement Checklist for Initial Submission Version 4 dated July 02 2018
UERMMMCI

Study-specific Documents (submit as needed)

- □ Investigator's Brochure (for clinical trials phase I, II, III) or Basic Product Information Document (for clinical trials phase IV) and other clinical trials outside of Phase 1 - 4
- □ Summary of all safety, pharmacological, pharmaceutical, and toxicological data (for study product such as pharmaceutical or device under investigation)
- □ Recruitment advertisements (as needed by the study protocol)
- □ Other information or documents for participants (such as diaries, etc.)
- □ Material Transfer Agreement (for any research involving transfer of biological specimens)
- □ Memorandum of Agreement (for collaborative studies)
- □ [RIHS ERC FORM 2(F)] Site Resources Checklist for Clinical Trial Outside UERMMMCI By UERMMMCI Personnel
- □ [RIHS ERC FORM 2(G)] Site Resources Checklist for Clinical Trial Outside UERMMMCI By non-UERMMMCI Personnel
- □ Previous ethical review approvals/clearances (for students/personnel of foreign universities researching in the Philippines or those with prior ethical review)
- □ Disclosure of previous ethical and/or scientific board reviews (with attached copy of conclusions, recommendations and incorporated changes)
- □ National Commission for Indigenous People (NCIP) Clearance (for studies with indigenous populations; can be processed while RIHS ERC review is on-going)
- Declaration of Conflict of Interest of the Principal Investigator/Co-investigators
- Disclosure of funding sources, sponsors, institutional affiliations and other possible sources of conflicts of interest
- Any additional materials submitted for approval (pls. specify)